Leap Therapeutics Announces Executive Leadership Changes
Christopher K. Mirabelli, Ph.D., will be stepping down from his role as President and Chief Executive Officer. Dr. Mirabelliwill continue to serve as the Chairman of Leap's Board of Directors and provide ongoing leadership and guidance around the Company's biomarker and research efforts. Douglas E. Onsi, Leap's Chief Financial Officer, is being named President and Chief Executive Officer, while maintaining his current role. Mr. Onsiwill also serve as a member of the Board of Directors. John Littlechildwill be stepping down from Leap's Board of Directors. Cynthia Sirard, M.D., Vice President, Clinical Research & Development, has been promoted to Chief Medical Officer. Mark O'Mahony, Vice President of Manufacturing, has been promoted to Chief Manufacturing Officer.
"I want to extend my gratitude to both Chris and John for the contributions they've made at Leap," said
"I would like to congratulate Cyndi and Mark. Thanks in large part to their efforts, we've made significant progress in advancing our DKN-01 program and securing BeiGene as a strategic partner. Their commitment to Leap and their efforts to advance our goal of delivering important new therapies for the treatment of cancer are greatly appreciated, and I look forward to continuing our work with them," said
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include statements regarding expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of future studies, enrollment in future studies, potential for the receipt of future option exercise, milestones or royalty payments from BeiGene, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially will be included in
Chief Financial Officer
View original content to download multimedia:http://www.prnewswire.com/news-releases/leap-therapeutics-announces-executive-leadership-changes-301025815.html